Home·Know Your Companions™·Esophageal squamous cell carcinoma (ESCC), and gastric, gastroesophageal junction (GEJ) and esophageal adenocarcinoma

Esophageal squamous cell carcinoma (ESCC), and gastric, gastroesophageal junction (GEJ) and esophageal adenocarcinoma

Solid tumor
Approvals
1
Therapies
6
Biomarkers
8
Mapped tests
6

Biomarkers used in this indication

Each approval combines this indication with specific biomarker criteria and a therapy. Select a therapy from the tables below to open its FDA-defined testing pathway.

Indication-specific biomarkers

Defined explicitly for Esophageal squamous cell carcinoma (ESCC), and gastric, gastroesophageal junction (GEJ) and esophageal adenocarcinoma in FDA labeling.

BiomarkerBiomarker criteriaTherapies
PD-L1
  • PD-L1 protein expression [Combined Positive Score (CPS) ≥ 1]
OPDIVO
Tumor-agnostic biomarkers

Defined at the solid tumor level and applicable to Esophageal squamous cell carcinoma (ESCC), and gastric, gastroesophageal junction (GEJ) and esophageal adenocarcinoma and other solid tumor cancers.

BiomarkerBiomarker criteriaTherapies
deficient mismatch repair (dMMR) proteins
  • MLH1, PMS2, MSH2 and MSH6
JEMPERLIKEYTRUDA
MSI-High
  • Microsatellite instability-High
KEYTRUDAJEMPERLI
NTRK1, NTRK2 and NTRK3
  • fusions
VITRAKVIROZLYTREK
RET
  • fusions
RETEVMO
TMB
  • TMB ≥ 10 mutations per megabase
KEYTRUDA

Therapies with biomarker-defined approvals

Each therapy below has at least one FDA companion diagnostic approval tied to Esophageal squamous cell carcinoma (ESCC), and gastric, gastroesophageal junction (GEJ) and esophageal adenocarcinoma. Select a therapy to view the specific approval and eligible tests.

Therapy
JEMPERLI
dostarlimag-gxly · GSK

deficient mismatch repair (dMMR) proteins (MLH1, PMS2, MSH2 and MSH6); MSI-High (Microsatellite instability-High)

2 approvalsView testing pathway →
Therapy
KEYTRUDA
pembrolizumab · Merck

deficient mismatch repair (dMMR) proteins (MLH1, PMS2, MSH2 and MSH6); MSI-High (Microsatellite instability-High); TMB (TMB ≥ 10 mutations per megabase)

3 approvalsView testing pathway →
Therapy
OPDIVO
nivolumab · Bristol Myers Squibb

PD-L1 (PD-L1 protein expression [Combined Positive Score (CPS) ≥ 1])

1 approvalView testing pathway →
Therapy
RETEVMO
selpercatinib · Eli Lilly

RET (fusions)

1 approvalView testing pathway →
Therapy
ROZLYTREK
entrectinib · Genentech

NTRK1, NTRK2 and NTRK3 (fusions)

1 approvalView testing pathway →
Therapy
VITRAKVI
larotrectinib · Bayer

NTRK1, NTRK2 and NTRK3 (fusions)

1 approvalView testing pathway →
This indication view is scoped to Esophageal squamous cell carcinoma (ESCC), and gastric, gastroesophageal junction (GEJ) and esophageal adenocarcinoma. You can also explore how it appears alongside other cancers in Know Your Companions™ by searching or filtering on the main map.